LJC242A
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $56,809 | 29 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $56,809 | 29 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED DOUBLE BLIND MULTICENTER STUDY TO ASSESS THE SAFETY TOLERABILITY AND EFFICACY OF A COMBINATION TREATMENT OF TROPIFEXOR LJN452 AND CENICRIVIROC CVC IN ADULT PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND LIVER FIBROSIS | Novartis Pharmaceuticals Corporation | $56,809 | 0 |
Top Doctors Receiving Payments for LJC242A
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Metairie, LA | $56,809 | 29 |
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $56,809
- Total Doctors 0
- Transactions 29
About LJC242A
LJC242A is a biological associated with $56,809 in payments to 0 healthcare providers, recorded across 29 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2018 to 2018. In 2018, $56,809 was paid across 29 transactions to 0 doctors.
The most common payment nature for LJC242A is "Unspecified" ($56,809, 100.0% of total).
LJC242A is associated with 1 research study, including "A RANDOMIZED DOUBLE BLIND MULTICENTER STUDY TO ASSESS THE SAFETY TOLERABILITY AND EFFICACY OF A COMBINATION TREATMENT OF TROPIFEXOR LJN452 AND CENICRIVIROC CVC IN ADULT PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND LIVER FIBROSIS" ($56,809).